Bioengineering is full of oversimplifications.

In this episode, I break down common myths that show up in research papers, startups, and even academic labs:

• “More power = more effect”

• “In vitro results translate directly to patients”

• “Reactive species are always harmful”

• “If it works once, it scales”

• “Plasma is just oxidation”

We’ll talk about dose-response behavior, mechanistic rigor, nonlinear biology, scaling challenges, and why systems thinking matters.

I’ve spent over a decade as a research professor and now run an R&D company focused on plasma systems for medical and environmental applications. This is a calm, technically grounded conversation about where bioengineering narratives often drift away from reality.

If you enjoy serious discussions about science without hype, th ...